IL2 and systemic lupus erythematosus: For example, the efficacy of low-dose IL-2 in the treatment of psoriasis patients has recently been confirmed [20], and clinical trials are currently under way using low-dose IL-2 in patients with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Behcet’s syndrome, Sjogren’s syndrome and autoimmune hepatitis [68].